Palonosetron Injection

Form: Injection

Strength: 0.25 mg/5 mL vial

Reference Brands: Aloxi(US) Palonosetron(EU)

Category: Oncology Cancer Care

Palonosetron Injection 0.25 mg/5 mL is a 5-HT3 receptor antagonist used to prevent chemotherapy-induced nausea and vomiting (CINV). It is particularly effective for patients undergoing highly emetogenic chemotherapy regimens. Approved in both the U.S. (under the brand name Aloxi) and the EU, Palonosetron is available as a single-dose 0.25 mg/5 mL vial for IV administration. This drug is essential in oncology B2B distribution, helping oncology centers and hospitals manage the side effects of chemotherapy, ensuring better patient outcomes by reducing nausea and vomiting after treatment.